

Robert N Jorissen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2219347/publications.pdf>

Version: 2024-02-01

52
papers

7,536
citations

159525

30
h-index

175177

52
g-index

53
all docs

53
docs citations

53
times ranked

12452
citing authors

#	ARTICLE	IF	CITATIONS
1	Hospitalizations Before and After Entry Into Long-Term Care. Journal of the American Medical Directors Association, 2022, , .	1.2	2
2	Trends in utilisation of plain X-rays by older Australians (2010â€“2019). BMC Geriatrics, 2022, 22, 100.	1.1	6
3	An integrated knowledge translation approach to address avoidable rehospitalisations and unplanned admissions for older people in South Australia: implementation and evaluation program plan. Implementation Science Communications, 2021, 2, 36.	0.8	4
4	Hospitalisation for lower respiratory viral infections in older people in residential aged care facilities. Australasian Journal on Ageing, 2021, , .	0.4	1
5	Predictors of shortâ€“term hospitalization and emergency department presentations in aged care. Journal of the American Geriatrics Society, 2021, 69, 3142-3156.	1.3	9
6	Effect of Dementia on Outcomes After Surgically Treated Hip Fracture in Older Adults. Journal of Arthroplasty, 2021, 36, 3181-3186.e4.	1.5	13
7	Predictors of hospitalisations and emergency department presentations shortly after entering a residential aged care facility in Australia: a retrospective cohort study. BMJ Open, 2021, 11, e057247.	0.8	9
8	National spending and uptake of mobile radiology services in aged care facilities: an opportunity to improve access remains. Internal Medicine Journal, 2021, 51, 2157-2159.	0.5	3
9	Incidence and predictors of common bile duct stones in patients with acute cholecystitis: a systematic literature review and metaâ€“analysis. ANZ Journal of Surgery, 2020, 90, 1598-1603.	0.3	19
10	The effect of frailty on outcomes of surgically treated hip fractures in older people. Bone, 2020, 136, 115327.	1.4	16
11	Evaluation of the transferability of survival calculators for stage II/III colon cancer across healthcare systems. International Journal of Cancer, 2019, 145, 132-142.	2.3	1
12	Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut, 2019, 68, 465-474.	6.1	52
13	Immunoscoreâ€”has it scored for colon cancer precision medicine?. Annals of Translational Medicine, 2018, 6, S23-S23.	0.7	6
14	<i>MACROD2</i> Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors. Cancer Discovery, 2018, 8, 988-1005.	7.7	55
15	<i>BRAF</i> V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. Clinical Cancer Research, 2017, 23, 104-115.	3.2	167
16	Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity. Gastroenterology, 2017, 153, 1082-1095.	0.6	55
17	Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer. Oncotarget, 2016, 7, 36474-36488.	0.8	23
18	Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncologica, 2015, 54, 487-492.	0.8	46

#	ARTICLE	IF	CITATIONS
19	Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis. <i>Molecular Cancer Research</i> , 2015, 13, 1185-1196.	1.5	13
20	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. <i>Science Signaling</i> , 2015, 8, ra82.	1.6	114
21	Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. <i>British Journal of Cancer</i> , 2015, 113, 979-988.	2.9	35
22	Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt β -catenin-mediated intestinal tumor growth and regeneration. <i>Science Signaling</i> , 2014, 7, ra92.	1.6	68
23	Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer. <i>Cancer Research</i> , 2014, 74, 3238-3247.	0.4	317
24	Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2V617F mutant allele detection. <i>BMC Cancer</i> , 2013, 13, 206.	1.1	14
25	<i>SMAD2</i> , <i>SMAD3</i> and <i>SMAD4</i> Mutations in Colorectal Cancer. <i>Cancer Research</i> , 2013, 73, 725-735.	0.4	260
26	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. <i>American Journal of Gastroenterology</i> , 2013, 108, 1785-1793.	0.2	120
27	<i>PIK3CA</i> and <i>PTEN</i> Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3285-3296.	3.2	107
28	Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/ β -catenin signalling thresholds for tumourigenesis. <i>Oncogene</i> , 2013, 32, 4675-4682.	2.6	117
29	<i>KRAS</i> Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1122-1130.	3.2	193
30	Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF ^{V600E} mutation. <i>International Journal of Cancer</i> , 2011, 128, 2075-2084.	2.3	200
31	PHLDA1 Expression Marks the Putative Epithelial Stem Cells and Contributes to Intestinal Tumorigenesis. <i>Cancer Research</i> , 2011, 71, 3709-3719.	0.4	86
32	Nonsense Mediated Decay Resistant Mutations Are a Source of Expressed Mutant Proteins in Colon Cancer Cell Lines with Microsatellite Instability. <i>PLoS ONE</i> , 2010, 5, e16012.	1.1	53
33	Structural elements and allosteric mechanisms governing regulation and catalysis of CSK-family kinases and their inhibition of Src-family kinases. <i>Growth Factors</i> , 2010, 28, 329-350.	0.5	34
34	A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. <i>Genome Biology</i> , 2010, 11, R92.	3.8	125
35	Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7642-7651.	3.2	395
36	Additivity in the Analysis and Design of HIV Protease Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 737-754.	2.9	23

#	ARTICLE	IF	CITATIONS
37	DNA Copy-Number Alterations Underlie Gene Expression Differences between Microsatellite Stable and Unstable Colorectal Cancers. <i>Clinical Cancer Research</i> , 2008, 14, 8061-8069.	3.2	84
38	BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. <i>Nucleic Acids Research</i> , 2007, 35, D198-D201.	6.5	1,493
39	Virtual Screening of Molecular Databases Using a Support Vector Machine. <i>Journal of Chemical Information and Modeling</i> , 2005, 45, 549-561.	2.5	241
40	Virtual Screening of Molecular Databases Using a Support Vector Machine.. <i>ChemInform</i> , 2005, 36, no.	0.1	1
41	CR1/CR2 Interactions Modulate the Functions of the Cell Surface Epidermal Growth Factor Receptor. <i>Journal of Biological Chemistry</i> , 2004, 279, 22387-22398.	1.6	75
42	Epidermal growth factor receptor: mechanisms of activation and signalling. <i>Experimental Cell Research</i> , 2003, 284, 31-53.	1.2	1,353
43	The Crystal Structure of a Truncated ErbB2 Ectodomain Reveals an Active Conformation, Poised to Interact with Other ErbB Receptors. <i>Molecular Cell</i> , 2003, 11, 495-505.	4.5	510
44	Epidermal growth factor receptor. , 2003, , 33-55.		51
45	Rapid Microscale Enzymic Semisynthesis of Epidermal Growth Factor (EGF) Analogues. <i>Growth Factors</i> , 2002, 20, 71-80.	0.5	5
46	Modeling the Epidermal Growth Factorâ€™Epidermal Growth Factor Receptor L2 Domain Interaction: Implications for the Ligand Binding Process. <i>Journal of Biomolecular Structure and Dynamics</i> , 2002, 19, 961-972.	2.0	8
47	The K252a Derivatives, Inhibitors for the PAK/MLK Kinase Family, Selectively Block the Growth of HAS Transformants. <i>Cancer Journal (Sudbury, Mass)</i> , 2002, 8, 328-336.	1.0	65
48	Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor Î±. <i>Cell</i> , 2002, 110, 763-773.	13.5	686
49	Identification of a Determinant of Epidermal Growth Factor Receptor Ligand-Binding Specificity Using a Truncated, High-Affinity Form of the Ectodomain. <i>Biochemistry</i> , 2001, 40, 8930-8939.	1.2	85
50	Stoichiometry, Kinetic and Binding Analysis of the Interaction between Epidermal Growth Factor (EGF) and the Extracellular Domain of the EGF Receptor. <i>Growth Factors</i> , 2000, 18, 11-29.	0.5	67
51	Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor. <i>Protein Science</i> , 2000, 9, 310-324.	3.1	21
52	Shapes of Molecules by Millimeter-Wave Spectroscopy:Â 2-Phenylethanol. <i>Journal of Physical Chemistry A</i> , 1999, 103, 7621-7626.	1.1	27